CSL appeared to be bulletproof for decades as Brian McNamee, its long-time chief executive turned chairman, led it the country’s fourth-largest company through string of offshore acquisitions, transforming the Melbourne-headquartered biotech into a world leader in plasma-based products.
But after decades of robust earnings and share price growth, the gloss has well and truly come off the healthcare giant over the last three years.